Company Overview and News

5
An evening walk down Dalal Street: MSP price hike gives a push to Indian markets; Sensex rallies over 250 points

2018-07-04 moneycontrol - 1
The S&P BSE Sensex rallied over 200 points on Wednesday despite negative global cues. The Nifty50 reclaimed 10,700 levels and closed above its short-term moving averages such as 5-EMA, 13-EMA, as well as 50-EMA which is a bullish sign.
UNICHEMLAB KOHINOOR 539275 532899 BHRQY SRTRANSFIN 511218 532454 512559 532783 506690 KSCL SRRQY MSL 500570 BHARTIARTL TATAMOTORS DAAWAT TTM

0
Agri stocks soar up to 10% after government hikes minimum support price of kharif crops

2018-07-04 moneycontrol
Shares of agriculture-related stocks rose on Wednesday as investors were upbeat on government's decision to hike minimum support price.
512559 532783 KOHINOOR 539275 KSCL MSL 532899 DAAWAT

8
Will compulsory delivery impact F&O trading?

2018-06-29 thehindubusinessline
KS Badri Narayanan Be prepared to have enough money in your account if you want to trade in the 46 F&O stocks that have been moved to the compulsory delivery category by the NSE starting July. This follows the SEBI diktat in March to align the cash and derivative segments of the market, through physical settlement for all stock derivatives in a phased and calibrated manner. To start with, the NSE has initiated compulsory delivery in 46 stocks.
SRI 532939 SREINFRA GODREJIND 533096 UBL IDBI 532899 532712 532478 533106 JUSTDIAL GRANULES 535648 RCOM OIL 532482 KSCL DCBBANK RPOWER SIFLY 523756 ALNSE 500116 UBHOLDINGS 535322 SRIA UNBWY REPCOHOME 532772 ADANIPOWER 507458 500164 JSTQY

1
Monsanto rival Kaveri Seed seeks bigger pie of Indian seed market

2018-06-12 livemint
Mumbai: Kaveri Seed Co., which competes with Monsanto Co. to sell hybrid seeds in India, is seeking a bigger share of the food crop market to reduce dependence on cotton seed, its breadwinner. The company gets about 60% of revenue from cotton seed sales and the remainder from vegetable seeds and grains including paddy and corn. It aims to reverse the proportion in three years, enticed by profit margins that are almost double that of the cotton segment, executive director C.
KSCL MON 532899

1
Kaveri Seed: Eyes on results, buyback

2018-05-23 thehindubusinessline
The board of Kaveri Seed Company will meet on Thursday to consider the audited financial results for the quarter/year ended March 31, 2018. The board will also consider a proposal for buyback of the equity shares of the company. If the proposal is approved by the board, shareholders would be keen to know the price, issue size and mode of buyback (whether open market purchase or through tender route).
KSCL 532899 SBAZ

0
Ashoka Pte sells 6.60 lakh shares of Kaveri Seed Company

2018-05-19 moneycontrol
On May 18, 2018 Ashoka PTE sold 6,60,815 shares of Kaveri Seed Company at Rs 500.13 on the NSE.
KSCL 532899

0
BNP Paribas Arbitrage buys 4.15 lakh shares of Kaveri Seed Company

2018-03-29 moneycontrol
On March 28, 2018 BNP Paribas Arbitrage bought 4,15,000 shares of Kaveri Seed Company at Rs 485.50 on the BSE.
KSCL 532899

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...